ketamine has been researched along with Idiopathic Parkinson Disease in 15 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Parkinson's disease is a chronic neurodegenerative disorder characterized by cardinal motor features, such as bradykinesia, but also vocal deficits (e." | 5.48 | Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease. ( Andreatini, R; Bruginski, E; Campos, FR; de Almeida Soares Hocayen, P; Kanazawa, LKS; Miyoshi, E; Schwarting, RKW; Stern, CAJ; Vecchia, DD; Vital, MABF; Wendler, E; Wöhr, M, 2018) |
| "Among patients with Parkinson's disease (PD), depression is prevalent and disabling, impacting both health outcomes and quality of life." | 2.58 | NMDA antagonists for treating the non-motor symptoms in Parkinson's disease. ( Bashmi, L; Danovitch, I; IsHak, WW; Jimenez, J; Olcott, W; Vanle, B, 2018) |
| "The most common features of Parkinson's disease (PD) are motor impairments, but many patients also present depression and memory impairment." | 1.62 | Ketamine reversed short-term memory impairment and depressive-like behavior in animal model of Parkinson's disease. ( Andreatini, R; Da Cunha, C; Hocayen, PAS; Kanazawa, LKS; Miyoshi, E; Takahashi, RN; Vecchia, DD; Vital, MABF; Wendler, E, 2021) |
| "(R)-ketamine has greater and longer-lasting antidepressant effects than (S)-ketamine in animal models of depression." | 1.56 | MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling. ( Chang, L; Fujita, A; Fujita, Y; Hashimoto, K; Pu, Y, 2020) |
| "Parkinson's disease is a chronic neurodegenerative disorder characterized by cardinal motor features, such as bradykinesia, but also vocal deficits (e." | 1.48 | Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease. ( Andreatini, R; Bruginski, E; Campos, FR; de Almeida Soares Hocayen, P; Kanazawa, LKS; Miyoshi, E; Schwarting, RKW; Stern, CAJ; Vecchia, DD; Vital, MABF; Wendler, E; Wöhr, M, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 4 (26.67) | 2.80 |
| Authors | Studies |
|---|---|
| Pottenger, AE | 1 |
| Bartlett, MJ | 1 |
| Sherman, SJ | 1 |
| Falk, T | 1 |
| Morrison, HW | 1 |
| Erdman, HB | 1 |
| Kornilov, E | 1 |
| Kahana, E | 1 |
| Zarchi, O | 1 |
| Reiner, J | 1 |
| Socher, A | 1 |
| Strauss, I | 1 |
| Firman, S | 1 |
| Israel, Z | 1 |
| Bergman, H | 1 |
| Tamir, I | 1 |
| Fujita, A | 1 |
| Fujita, Y | 1 |
| Pu, Y | 1 |
| Chang, L | 1 |
| Hashimoto, K | 1 |
| Vecchia, DD | 2 |
| Kanazawa, LKS | 2 |
| Wendler, E | 2 |
| Hocayen, PAS | 1 |
| Vital, MABF | 2 |
| Takahashi, RN | 1 |
| Da Cunha, C | 2 |
| Miyoshi, E | 2 |
| Andreatini, R | 2 |
| de Almeida Soares Hocayen, P | 1 |
| Bruginski, E | 1 |
| Campos, FR | 1 |
| Stern, CAJ | 1 |
| Wöhr, M | 1 |
| Schwarting, RKW | 1 |
| Vanle, B | 1 |
| Olcott, W | 1 |
| Jimenez, J | 1 |
| Bashmi, L | 1 |
| Danovitch, I | 1 |
| IsHak, WW | 1 |
| Lerner, RP | 1 |
| Bimpisidis, Z | 2 |
| Agorastos, S | 1 |
| Scherrer, S | 1 |
| Dewey, SL | 1 |
| Cenci, MA | 2 |
| Eidelberg, D | 1 |
| Öberg, CM | 1 |
| Maslava, N | 1 |
| Lundblad, C | 1 |
| Wright, JJ | 1 |
| Goodnight, PD | 1 |
| McEvoy, MD | 1 |
| Pan, J | 1 |
| Xiao, Q | 1 |
| Sheng, CY | 1 |
| Hong, Z | 1 |
| Yang, HQ | 1 |
| Wang, G | 1 |
| Ding, JQ | 1 |
| Chen, SD | 1 |
| Lettieri, C | 1 |
| Rinaldo, S | 1 |
| Devigili, G | 1 |
| Pauletto, G | 1 |
| Verriello, L | 1 |
| Budai, R | 1 |
| Fadiga, L | 1 |
| Oliynyk, A | 1 |
| Mondani, M | 1 |
| D'Auria, S | 1 |
| Skrap, M | 1 |
| Eleopra, R | 1 |
| Ferro, MM | 1 |
| Angelucci, ME | 1 |
| Anselmo-Franci, JA | 1 |
| Canteras, NS | 1 |
| Hetherington, A | 1 |
| Rosenblatt, RM | 1 |
| Hershey, T | 1 |
| Black, KJ | 1 |
| Carl, JL | 1 |
| Perlmutter, JS | 1 |
| Carlsson, M | 1 |
| Svensson, A | 1 |
| Carlsson, A | 1 |
1 review available for ketamine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
NMDA antagonists for treating the non-motor symptoms in Parkinson's disease.
Topics: Antidepressive Agents; Antiparkinson Agents; Depression; Excitatory Amino Acid Antagonists; Humans; | 2018 |
14 other studies available for ketamine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Evaluation of microglia in a rodent model of Parkinson's disease primed with L-DOPA after sub-anesthetic ketamine treatment.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Corpus Striatum; Disease Models, A | 2021 |
Asleep DBS under ketamine sedation: Proof of concept.
Topics: Anesthesia, General; Brain Neoplasms; Deep Brain Stimulation; Humans; Ketamine; Microelectrodes; Par | 2022 |
MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Anesthetics, Dissociative; | 2020 |
Ketamine reversed short-term memory impairment and depressive-like behavior in animal model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Depression; Disease Models, Animal; Imipramine; Ketamine; Male; Memory, S | 2021 |
Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease.
Topics: Anhedonia; Animals; Depression; Disease Models, Animal; Gait; Imipramine; Ketamine; Male; Nerve Dege | 2018 |
Dissociation of metabolic and hemodynamic levodopa responses in the 6-hydroxydopamine rat model.
Topics: Analgesics; Animals; Antiparkinson Agents; Cerebrovascular Circulation; Disease Models, Animal; Fema | 2016 |
Differential effects of gaseous versus injectable anesthetics on changes in regional cerebral blood flow and metabolism induced by l-DOPA in a rat model of Parkinson's disease.
Topics: Anesthetics; Animals; Basal Ganglia; Cerebrovascular Circulation; Dyskinesia, Drug-Induced; Dyskines | 2017 |
The utility of ketamine for the preoperative management of a patient with Parkinson's disease.
Topics: Anesthesia, Inhalation; Anesthetics, Dissociative; Female; Humans; Intubation, Intratracheal; Ketami | 2009 |
Blockade of the translocation and activation of c-Jun N-terminal kinase 3 (JNK3) attenuates dopaminergic neuronal damage in mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcysteine; Animals; Blotting, Western; Cell Nucle | 2009 |
Deep brain stimulation: Subthalamic nucleus electrophysiological activity in awake and anesthetized patients.
Topics: Aged; Anesthesia, General; Anesthesia, Local; Deep Brain Stimulation; Female; Humans; Ketamine; Male | 2012 |
Neuroprotective effect of ketamine/xylazine on two rat models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Anesthetics, Combined; Animals; Biogenic Monoamines; C | 2007 |
Ketamine and paralysis agitans.
Topics: Aged; Anesthesia, Intravenous; Humans; Ketamine; Male; Parkinson Disease | 1980 |
Dopa-induced blood flow responses in nonhuman primates.
Topics: Anesthetics, Dissociative; Animals; Antiparkinson Agents; Arousal; Carbidopa; Cerebrovascular Circul | 2000 |
Synergistic interactions between muscarinic antagonists, adrenergic agonists and NMDA antagonists with respect to locomotor stimulatory effects in monoamine-depleted mice.
Topics: Adrenergic alpha-Agonists; Animals; Atropine; Biperiden; Clonidine; Disease Models, Animal; Dizocilp | 1991 |